1258003-93-8
Chemical Structure
(R)-MMP408
- CAS No.: 1258003-93-8
- Formula:C19H20N2O7S
- Molecular Weight:420.44
IUPAC Name: ((8-((methoxycarbonyl)amino)dibenzo[b,d]furan-3-yl)sulfonyl)-D-valine
InChIKey: MKAIHDAGQJQAHA-QGZVFWFLSA-N
SMILES: CC(C)[C@H](C(O)=O)NS(=O)(C1=CC=C2C(OC3=CC=C(NC(OC)=O)C=C23)=C1)=O
Biological Activity: (R)-MMP408 is an isomer of MMP408 (HY-12093). MMP408 is an orally active MMP-12 inhibitor (IC50=2.0 nM for hMMP-12) that effectively interferes with the epithelial-mesenchymal transition (EMT) process. MMP408 significantly upregulates the expression of E-cadherin in nasal epithelial cells, while inhibiting mesenchymal markers such as vimentin, α-smooth muscle actin and fibronectin, thereby reversing the EMT phenotype. MMP408 is used in studies of airway remodeling-related diseases, including chronic rhinosinusitis with nasal polyps, chronic obstructive pulmonary disease (COPD) and asthma[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
(R)-MMP408 | 99.63% | (R)-MMP408 is an isomer of MMP408 (HY-12093). MMP408 is an orally active MMP-12 inhibitor (IC50=2.0 nM for hMMP-12) that effectively interferes with the epithelial-mesenchymal transition (EMT) process. MMP408 significantly upregulates the expression of E-cadherin in nasal epithelial cells, while inhibiting mesenchymal markers such as vimentin, α-smooth muscle actin and fibronectin, thereby reversing the EMT phenotype. MMP408 is used in studies of airway remodeling-related diseases, including chronic rhinosinusitis with nasal polyps, chronic obstructive pulmonary disease (COPD) and asthma. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Park J H, et al. Matrix metalloproteinase-12 by M2 macrophages induced epithelial to mesenchymal transition in chronic rhinosinusitis with nasal polyps[J]. Plos one, 2024, 19(12): e0313097.
- [2]. Baggio C, et al. Therapeutic targeting of MMP-12 for the treatment of chronic obstructive pulmonary disease[J]. Journal of medicinal chemistry, 2020, 63(21): 12911-12920.
- [3]. Wu Y, et al. Discovery of potent and selective matrix metalloprotease 12 inhibitors for the potential treatment of chronic obstructive pulmonary disease (COPD). Bioorg Med Chem Lett. 2012;22(1):138-143. [Content Brief]
